Login to Your Account

Financings Roundup

Following Ravicti Win in UCD, Hyperion Seeks $59.7M for HE

By Marie Powers
Staff Writer

Friday, March 8, 2013
One month after gaining FDA approval for Ravicti (glycerol phenylbutyrate) in the chronic management of certain urea cycle disorders (UCDs), orphan disease specialist Hyperion Therapeutics Inc. upsized a public offering of about 2.9 million shares of common stock, priced at $20.75, seeking to raise $59.7 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription